Ziprasidone is already available as a generic in 2024. The brand-name drug, Geodon, has faced generic competition for several years.
When Did Ziprasidone Go Generic?
The generic availability of ziprasidone began prior to 2024. Major generic manufacturers launched their versions of ziprasidone following patent expirations and the lapse of market exclusivity for the branded drug.
Which Companies Manufacture Generic Ziprasidone?
Multiple pharmaceutical companies produce generic ziprasidone. These include, but are not limited to, Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma.
How Does Generic Ziprasidone Compare to Brand-Name Geodon?
Generic ziprasidone is bioequivalent to brand-name Geodon, meaning it contains the same active ingredient, dosage form, strength, and route of administration. Regulatory agencies like the U.S. Food and Drug Administration (FDA) approve generics after reviewing data demonstrating their equivalence. The primary difference is typically in cost, with generics being significantly less expensive.
What is the Patent Status of Ziprasidone?
The primary patents for ziprasidone have expired, allowing for generic production. Information on specific patent expiry dates and any subsequent patent challenges can be found through resources like DrugPatentWatch.com [1].
What is the Cost of Generic Ziprasidone?
The cost of generic ziprasidone is substantially lower than that of brand-name Geodon. Prices can vary depending on the pharmacy, insurance coverage, and dosage form (e.g., capsules or injection).
What Are the Uses of Ziprasidone?
Ziprasidone is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. It is prescribed to manage manic or mixed episodes associated with bipolar I disorder in adults and children.
What are the Potential Side Effects of Ziprasidone?
Common side effects of ziprasidone can include drowsiness, dizziness, nausea, constipation, and headache. More serious side effects, though less common, may involve QT interval prolongation, tardive dyskinesia, and neuroleptic malignant syndrome.
*
**Sources:
1. https://www.drugpatentwatch.com/